BTIG Research Reaffirms “Buy” Rating for Harrow (NASDAQ:HROW)

Harrow (NASDAQ:HROW)‘s stock had its “buy” rating reiterated by analysts at BTIG Research in a report issued on Wednesday, Benzinga reports. They currently have a $63.00 target price on the stock. BTIG Research‘s price target indicates a potential upside of 107.51% from the stock’s previous close.

Several other research analysts also recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Harrow in a report on Friday, October 16th. Wall Street Zen upgraded Harrow from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Leerink Partners assumed coverage on Harrow in a report on Wednesday, September 9th. They set an “outperform” rating and a $45.00 target price for the company. Finally, Zacks Research lowered Harrow from a “hold” rating to a “strong sell” rating in a research report on Tuesday, November 3rd. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $66.17.

Harrow Stock Up 10.5%

HROW stock opened at $30.36 on Wednesday. The company has a debt-to-equity ratio of 19.70, a current ratio of 2.24 and a quick ratio of 2.08. Harrow has a one year low of $25.76 and a one year high of $54.85. The company’s 50 day moving average price is $31.30 and its two-hundred day moving average price is $37.74.

Harrow (NASDAQ:HROW) last announced its quarterly earnings data on Monday, November 9th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.06. Harrow had a negative net margin of 9.39% and a negative return on equity of 68.20%. The company had revenue of $99.30 million during the quarter, compared to analysts’ expectations of $98.59 million. Equities research analysts forecast that Harrow will post -0.02 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Amir Shojaei sold 11,250 shares of the company’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $40.00, for a total transaction of $450,000.00. Following the completion of the sale, the insider directly owned 11,250 shares in the company, valued at $450,000. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 12.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Harrow

A number of hedge funds have recently modified their holdings of HROW. KBC Group NV bought a new position in shares of Harrow during the first quarter valued at about $31,000. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Harrow by 15.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 6,840 shares of the company’s stock worth $215,000 after purchasing an additional 908 shares during the period. Sterling Capital Management LLC grew its stake in shares of Harrow by 836.8% in the third quarter. Sterling Capital Management LLC now owns 1,068 shares of the company’s stock worth $33,000 after purchasing an additional 954 shares during the last quarter. First Bancorp Inc ME bought a new stake in shares of Harrow in the second quarter worth about $64,000. Finally, State of Wyoming bought a new stake in shares of Harrow in the second quarter worth about $72,000. Hedge funds and other institutional investors own 72.76% of the company’s stock.

Harrow News Roundup

Here are the key news stories impacting Harrow this week:

• Positive Sentiment: Third-quarter revenue reached a record $99.3 million, up 39% year over year. Branded revenue rose 62% to $83.5 million, demonstrating strong growth in Harrow’s core products. Harrow third-quarter results
• Positive Sentiment: Harrow forecast fourth-quarter revenue of approximately $136 million to $151 million and reaffirmed 2026 revenue guidance of $350 million to $365 million, modestly above the roughly $349.7 million consensus estimate. Harrow revenue and EBITDA outlook
• Neutral Sentiment: Harrow reported $9.8 million in GAAP net income, versus a $17.3 million loss in the prior quarter. The result included a $5 million litigation-settlement gain, so it may not reflect recurring operating performance. Harrow third-quarter results
• Negative Sentiment: The company lowered its full-year 2026 adjusted EBITDA outlook to more than $40 million, from its prior range of $80 million to $100 million. Third-quarter adjusted EBITDA was $21.2 million, below $22.8 million a year earlier. The sharp outlook reduction could temper enthusiasm for the strong revenue growth. Harrow earnings guidance

Harrow Company Profile

Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.